CRISPR Therapeutics (CRSP) Competitors $65.13 +10.04 (+18.22%) Closing price 04:00 PM EasternExtended Trading$64.90 -0.23 (-0.35%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock CRSP vs. ALLO, AXSM, BEAM, EDIT, KALA, MRNA, NTLA, VRTX, INSM, and TEVAShould you be buying CRISPR Therapeutics stock or one of its competitors? The main competitors of CRISPR Therapeutics include Allogene Therapeutics (ALLO), Axsome Therapeutics (AXSM), Beam Therapeutics (BEAM), Editas Medicine (EDIT), KALA BIO (KALA), Moderna (MRNA), Intellia Therapeutics (NTLA), Vertex Pharmaceuticals (VRTX), Insmed (INSM), and Teva Pharmaceutical Industries (TEVA). These companies are all part of the "medical" sector. CRISPR Therapeutics vs. Its Competitors Allogene Therapeutics Axsome Therapeutics Beam Therapeutics Editas Medicine KALA BIO Moderna Intellia Therapeutics Vertex Pharmaceuticals Insmed Teva Pharmaceutical Industries Allogene Therapeutics (NASDAQ:ALLO) and CRISPR Therapeutics (NASDAQ:CRSP) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, valuation, dividends, profitability, risk, analyst recommendations, institutional ownership and media sentiment. Does the media refer more to ALLO or CRSP? In the previous week, CRISPR Therapeutics had 15 more articles in the media than Allogene Therapeutics. MarketBeat recorded 17 mentions for CRISPR Therapeutics and 2 mentions for Allogene Therapeutics. Allogene Therapeutics' average media sentiment score of 1.48 beat CRISPR Therapeutics' score of 1.00 indicating that Allogene Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Allogene Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive CRISPR Therapeutics 8 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has higher earnings and valuation, ALLO or CRSP? Allogene Therapeutics has higher earnings, but lower revenue than CRISPR Therapeutics. CRISPR Therapeutics is trading at a lower price-to-earnings ratio than Allogene Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAllogene Therapeutics$20K13,670.63-$257.59M-$1.23-1.02CRISPR Therapeutics$37.31M150.75-$366.25M-$4.52-14.41 Do analysts rate ALLO or CRSP? Allogene Therapeutics currently has a consensus price target of $8.44, indicating a potential upside of 575.56%. CRISPR Therapeutics has a consensus price target of $71.75, indicating a potential upside of 10.16%. Given Allogene Therapeutics' stronger consensus rating and higher probable upside, equities research analysts clearly believe Allogene Therapeutics is more favorable than CRISPR Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Allogene Therapeutics 0 Sell rating(s) 1 Hold rating(s) 9 Buy rating(s) 0 Strong Buy rating(s) 2.90CRISPR Therapeutics 1 Sell rating(s) 6 Hold rating(s) 10 Buy rating(s) 0 Strong Buy rating(s) 2.53 Do institutionals & insiders have more ownership in ALLO or CRSP? 83.6% of Allogene Therapeutics shares are owned by institutional investors. Comparatively, 69.2% of CRISPR Therapeutics shares are owned by institutional investors. 13.2% of Allogene Therapeutics shares are owned by company insiders. Comparatively, 4.3% of CRISPR Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth. Which has more volatility & risk, ALLO or CRSP? Allogene Therapeutics has a beta of 0.31, meaning that its stock price is 69% less volatile than the S&P 500. Comparatively, CRISPR Therapeutics has a beta of 1.82, meaning that its stock price is 82% more volatile than the S&P 500. Is ALLO or CRSP more profitable? Allogene Therapeutics has a net margin of 0.00% compared to CRISPR Therapeutics' net margin of -1,023.64%. CRISPR Therapeutics' return on equity of -20.08% beat Allogene Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Allogene TherapeuticsN/A -52.98% -41.28% CRISPR Therapeutics -1,023.64%-20.08%-17.13% SummaryAllogene Therapeutics beats CRISPR Therapeutics on 10 of the 16 factors compared between the two stocks. Get CRISPR Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CRSP and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CRSP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CRSP vs. The Competition Export to ExcelMetricCRISPR TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$4.76B$2.91B$5.52B$9.41BDividend YieldN/A2.45%3.80%4.04%P/E Ratio-14.4119.8828.0419.84Price / Sales150.75305.11429.5399.59Price / CashN/A43.1635.8457.94Price / Book2.887.678.125.65Net Income-$366.25M-$55.28M$3.25B$258.00M7 Day Performance14.67%2.50%0.97%2.09%1 Month Performance46.59%11.70%7.36%11.13%1 Year Performance15.87%4.89%31.31%18.40% CRISPR Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CRSPCRISPR Therapeutics2.69 of 5 stars$65.13+18.2%$71.75+10.2%-8.9%$4.76B$37.31M-14.41460Insider TradeAnalyst RevisionGap UpHigh Trading VolumeALLOAllogene Therapeutics3.6675 of 5 stars$1.26-2.0%$8.44+572.9%-63.7%$276.69M$20K-1.03310News CoveragePositive NewsAXSMAxsome Therapeutics4.7309 of 5 stars$111.37+2.2%$172.33+54.7%+34.0%$5.50B$385.69M-19.36380Analyst RevisionBEAMBeam Therapeutics2.0658 of 5 stars$21.06-0.5%$48.75+131.5%-24.1%$2.12B$63.52M-4.57510Gap UpEDITEditas Medicine4.0963 of 5 stars$2.83-1.8%$4.70+66.1%-52.3%$237.32M$32.31M-0.93230News CoveragePositive NewsKALAKALA BIO3.8514 of 5 stars$5.81-0.7%$13.00+123.8%-20.0%$37.47M$3.89M-0.7130MRNAModerna4.2835 of 5 stars$32.99-1.9%$46.61+41.3%-74.0%$12.80B$3.24B-3.795,800Trending NewsOptions VolumeAnalyst RevisionNTLAIntellia Therapeutics4.4128 of 5 stars$11.88+3.0%$33.37+180.9%-56.8%$1.23B$57.88M-2.27600Gap UpVRTXVertex Pharmaceuticals4.7262 of 5 stars$472.44+0.8%$511.71+8.3%-5.1%$121.50B$11.02B-120.706,100Positive NewsAnalyst RevisionINSMInsmed3.8659 of 5 stars$101.20+3.1%$108.07+6.8%+37.9%$19.21B$381.03M-17.021,271Positive NewsAnalyst ForecastInsider TradeTEVATeva Pharmaceutical Industries4.1195 of 5 stars$16.400.0%$24.71+50.7%-0.4%$18.82B$16.54B-14.2736,830 Related Companies and Tools Related Companies Allogene Therapeutics Alternatives Axsome Therapeutics Alternatives Beam Therapeutics Alternatives Editas Medicine Alternatives KALA BIO Alternatives Moderna Alternatives Intellia Therapeutics Alternatives Vertex Pharmaceuticals Alternatives Insmed Alternatives Teva Pharmaceutical Industries Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CRSP) was last updated on 7/18/2025 by MarketBeat.com Staff From Our PartnersUtah’s New Oil FindThe Real Reason 218,000 Acres Just Vanished The government just quietly leased 218,000 acres in the middle ...Stansberry Research | SponsoredCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | Sponsored[ATTENTION] This Crypto Rocket Is About Launch…Every crypto bull market ends with a final surge — the window where fortunes are made fast. According to tw...Crypto Swap Profits | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredAI Meltdown Imminent: Dump These Stocks Now!If you have any money in the markets, especially in AI stocks… Please click here to see Elon Musk’s new inv...Paradigm Press | SponsoredHedge fund legend humiliates Bitcoin tradersLarry Benedict made $274 million trading on Wall Street… Barron’s ranked his hedge fund in the top 1% world...Brownstone Research | SponsoredFREE BUY ALERT: These 3 tiny AI stocks could surgeWe're living in unprecedented times. Most people think it's too late to get into AI right now … That the...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CRISPR Therapeutics AG Please log in to your account or sign up in order to add this asset to your watchlist. Share CRISPR Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
